论文部分内容阅读
目的探讨中性粒细胞明胶酶相关脂质载运蛋白(NGAL)、血管内皮生长因子-C(VEGF-C)及CA125与子宫内膜癌临床病理特征的关系。方法对30例子宫内膜癌患者及正常妇女内膜组织中NGAL、VEGF-C及CA125进行免疫组化检测。结果子宫内膜癌患者与正常妇女增生期子宫内膜组织中NGAL、VEGF-C及CA125的表达差异有统计学意义(P<0.05),且子宫内膜癌组织中NGAL、VEGF-C及CA125的表达与FIGO临床病理分期密切相关(P<0.05)。结论子宫内膜中的NGAL、VEGF-C及CA125变化与癌细胞的侵袭有关,可作为临床分子水平治疗子宫内膜癌的特异性靶点,并有利于生物治疗的进行。
Objective To investigate the relationship between neutrophil gelatinase-associated lipid transporter (NGAL), vascular endothelial growth factor-C (VEGF-C) and CA125 and clinicopathological features of endometrial carcinoma. Methods Immunohistochemistry was used to detect the expression of NGAL, VEGF-C and CA125 in 30 cases of endometrial carcinoma and normal endometrium. Results There was significant difference in the expression of NGAL, VEGF-C and CA125 between proliferative endometrium and normal endometrial carcinoma (P <0.05), and the expression of NGAL, VEGF-C and CA125 in endometrial carcinoma The expression was closely related to the clinical stage of FIGO (P <0.05). Conclusion The changes of NGAL, VEGF-C and CA125 in endometrium are related to the invasion of cancer cells, which can be used as a specific target for the treatment of endometrial cancer at clinical molecular level, and are beneficial to the progress of biological therapy.